Opinion
Video
Metastatic Castration-Sensitive Prostate Cancer (mCSPC) Overview
Author(s):
Panelists discuss how metastatic castration-sensitive prostate cancer (mCSPC) is managed with a combination of androgen deprivation therapy, chemotherapy, and novel agents like such as abiraterone and enzalutamide, aiming to improve survival outcomes while addressing the disease's high metastatic burden.
Related Content
